L-Carn (Levocarnitine)

• L-Carn is used to address disorders of carnitine metabolism and related energy‑production pathways.
• Primary carnitine deficiency: restores intracellular carnitine stores and supports fatty‑acid oxidation.
• Secondary carnitine deficiency: compensates for acquired loss of carnitine and improves metabolic stability.
• Metabolic disorders requiring carnitine supplementation: enhances mitochondrial β‑oxidation and assists in energy generation.

• Levocarnitine acts as a carrier molecule that transports long‑chain fatty acids across the inner mitochondrial membrane. By forming acyl‑carnitine esters, it enables β‑oxidation of fatty acids, thereby facilitating ATP production and supporting cellular energy metabolism, especially in tissues with high oxidative demand.

Adverse reactions may occur with intravenous levocarnitine administration.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Vomiting: occasional emesis following infusion.
• Headache: transient cranial discomfort.
• Mild hypotension: temporary drop in blood pressure.
• Injection site pain: local discomfort at the infusion site.
• Metallic taste: brief alteration in taste perception.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Severe hypotension: marked blood pressure decline.
• Arrhythmia: irregular heart rhythm.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Metabolic acidosis: significant acid‑base imbalance.
• Seizures: rare neurologic events.

Safety considerations should be observed when using L-Carn.

• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic disease: use with caution; observe liver function tests.
• Concomitant valproic acid: increased risk of hyperammonemia; monitor ammonia levels.
• Pregnancy: safety not established; weigh potential benefits against risks.
• Breastfeeding: unknown excretion in milk; consider alternatives.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions require attention.

Major Interactions (Avoid)

• Valproic acid: may increase ammonia accumulation.
• Warfarin: possible alteration of anticoagulant effect.
• Phenobarbital: induces metabolism, reducing levocarnitine levels.
• Cyclosporine: heightened nephrotoxicity risk.
• High-dose insulin: may exacerbate hypoglycemia.

Moderate Interactions (Monitor Closely)

• Diuretics: electrolyte shifts may affect carnitine balance.
• Statins: combined muscle toxicity potential.
• Antibiotics (e.g., carbapenems): may interfere with renal clearance.
• Antiepileptics: monitor for additive CNS effects.
• Hormonal contraceptives: observe for altered plasma concentrations.